LSP 5 had a final closing at $280 million in May 2016 (here is the press release
). It is the successor fund to our previous closed-end investment funds that we have raised over the past 30 years, and it is our largest fund to date. Through the years, we have committed to the same and proven investment strategy and focus. LSP 5, just like its predecessors, is investing in healthcare companies developing novel and ground-breaking products and technologies that provide solutions to unmet medical needs. This strategy and focus has paved the way for LSP to become one of Europe’s foremost names in healthcare investing.
Over the years, we have supported the development of numerous companies, providing them with the capital required to grow and flourish. Typically, we adopt an active, hands-on approach to our investments. We work closely with portfolio company management teams, co-directors and major co-investors in an effort to achieve the long-term goals that we set together from the outset. Our investments are primarily located in Europe and occasionally in the US, and made at various stages of a company's development. Historically, we have made seed investments in assets at the research phase and formed companies around them. We also make later-stage investments requiring less intense guidance and support, but more capital. In addition, we have also made several investments in companies that were spun out from large pharmaceutical companies around assets that were no longer deemed of strategic interest to the parent companies.
The LSP 5 fund has already done several highly promising investments and targets to make up to 18 investments. Like all its predecessor funds, LSP 5 appealed to investors interested in a sector creating breakthrough products and technologies that make a very real difference to patients. Typical investors include large institutions, fund-of-funds, family offices, high net worth individuals and strategic investors such as pharmaceutical companies. One example of a pharmaceutical company investing in LSP 5 is Bristol-Myers Squibb who has entered in a strategic collaboration with LSP to identify European breakthrough technologies (here is the press release
People who have questions about our funds and would like to receive more information, are kindly asked to email René Kuijten at firstname.lastname@example.org
; alternatively, please contact one of our offices via +31(20)664 55 00 (Amsterdam), +49(89) 330 66 60 (Munich) or +1 (781) 472 2743 (Boston) and we will ensure you are connected with René Kuijten or one of his colleagues.